Ascendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of “Buy” by Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been given a consensus rating of “Buy” by the seventeen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $256.7333.

A number of brokerages have commented on ASND. Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, November 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Wedbush reissued an “outperform” rating and set a $220.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, November 18th. Finally, Stifel Nicolaus upped their price objective on Ascendis Pharma A/S from $254.00 to $256.00 and gave the company a “buy” rating in a research note on Thursday, December 11th.

Ascendis Pharma A/S Stock Up 1.7%

Shares of Ascendis Pharma A/S stock opened at $212.71 on Thursday. Ascendis Pharma A/S has a 12-month low of $118.03 and a 12-month high of $229.94. The stock has a market cap of $13.17 billion, a P/E ratio of -47.91 and a beta of 0.45. The business’s 50 day moving average is $205.94 and its 200-day moving average is $193.46.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The company had revenue of $250.71 million for the quarter, compared to analyst estimates of $246.91 million. On average, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds have recently added to or reduced their stakes in the business. Perceptive Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the 2nd quarter worth approximately $166,367,000. Wellington Management Group LLP boosted its stake in shares of Ascendis Pharma A/S by 95.9% in the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after buying an additional 880,836 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Ascendis Pharma A/S by 2,722.9% in the third quarter. Principal Financial Group Inc. now owns 793,677 shares of the biotechnology company’s stock valued at $157,791,000 after buying an additional 765,561 shares during the period. Vestal Point Capital LP grew its position in Ascendis Pharma A/S by 200.0% during the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock worth $119,286,000 after buying an additional 400,000 shares in the last quarter. Finally, Spyglass Capital Management LLC bought a new position in Ascendis Pharma A/S during the 3rd quarter worth $77,267,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.